secwatch.observer — SEC 8-K summary
======================================

Issuer:     CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK:        0001369568
Form:       8-K
Filed at:   2025-06-02T23:59:59+00:00
Accession:  0001193125-25-133348
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Catalyst Pharma appoints Dr. William Andrews as CMO; Dr. Ingenito retires
-------------------------------------------------------------------------

- Gary Ingenito retired as Chief Medical and Regulatory Officer effective June 1, 2025; no disagreement with management.
- William Andrews appointed as new Chief Medical Officer effective June 2, 2025, reporting to CEO Richard Daly.
- Andrews brings 24 years of biopharma experience, including CMO roles at Flexion, Akcea, and Acer Therapeutics.
- Ingenito will serve as a consultant to assist with the transition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1369568/000119312525133348/0001193125-25-133348-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1369568/000119312525133348/d17589d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-133348

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer